Display options
Cite
Mizrahi M, Adar T, Orenbuch-Harroch E, et al. Non-ST Elevation Myocardial Infraction after High Dose Intravenous Immunoglobulin Infusion. Case Rep Med. 2010;2009:861370doi: 10.1155/2009/861370.
Mizrahi, M., Adar, T., Orenbuch-Harroch, E., & Elitzur, Y. (2009). Non-ST Elevation Myocardial Infraction after High Dose Intravenous Immunoglobulin Infusion. Case reports in medicine, 2009861370. https://doi.org/10.1155/2009/861370
Mizrahi, Meir, et al. "Non-ST Elevation Myocardial Infraction after High Dose Intravenous Immunoglobulin Infusion." Case reports in medicine vol. 2009 (2009): 861370. doi: https://doi.org/10.1155/2009/861370
Mizrahi M, Adar T, Orenbuch-Harroch E, Elitzur Y. Non-ST Elevation Myocardial Infraction after High Dose Intravenous Immunoglobulin Infusion. Case Rep Med. 2009;2009:861370. doi: 10.1155/2009/861370. Epub 2010 Feb 22. PMID: 20182639; PMCID: PMC2825772.
Copy Download .nbib Format: NLM
Share it on

Case Rep Med. 2009;2009:861370. doi: 10.1155/2009/861370. Epub 2010 Feb 22.

Non-ST Elevation Myocardial Infraction after High Dose Intravenous Immunoglobulin Infusion.

Case reports in medicine

Meir Mizrahi, Tomer Adar, Efrat Orenbuch-Harroch, Yair Elitzur

Affiliations

  1. Internal Medicine A, Department of Medicine, Hebrew University-Hadassah Medical Center, Jerusalem IL 91120, Israel.

PMID: 20182639 PMCID: PMC2825772 DOI: 10.1155/2009/861370

Abstract

Intravenous immunoglobulins (IVIgs) are used for several indications, including autoimmune conditions. IVIg treatment is associated with several possible adverse reactions including induction of a hypercoagulable state. We report a 76-year-old woman treated with IVIg for myasthenia gravis, which developed chest pain and weakness following IVIg infusion. The symptoms were associated with ST segment depression in V4-6 and elevated troponin levels. The patient was diagnosed with non-ST elevation myocardial infarction (NSTEMI). The patient had no significant risk factor besides age and a cardiac perfusion scan was interpreted as normal (the patient refused to undergo cardiac catheterization). This case is compatible with IVIg-induced hypercoagulability resulting in NSTEMI. Cardiac evaluation should therefore be considered prior to initiation of IVIg treatment especially in patients with multiple cardiovascular risks.

References

  1. Lancet. 1992 Mar 14;339(8794):662-4 - PubMed
  2. Ann Hematol. 2004 Oct;83(10):661-5 - PubMed
  3. Nat Clin Pract Rheumatol. 2007 May;3(5):262-72 - PubMed
  4. Autoimmun Rev. 2007 Mar;6(4):257-9 - PubMed
  5. Eur J Pediatr. 2007 Sep;166(9):915-9 - PubMed
  6. Ann Pharmacother. 2007 Oct;41(10):1604-10 - PubMed
  7. Pediatr Neurol. 2008 Aug;39(2):123-5 - PubMed
  8. Rheumatol Int. 2005 Apr;25(3):211-4 - PubMed
  9. Lancet. 1985 Aug 31;2(8453):464-8 - PubMed
  10. Clin Exp Immunol. 1994 Jul;97 Suppl 1:79-83 - PubMed
  11. J Neuroimaging. 2005 Apr;15(2):188-92 - PubMed
  12. JAMA. 2004 May 19;291(19):2367-75 - PubMed
  13. N Engl J Med. 1991 Jun 6;324(23):1633-9 - PubMed
  14. Ann Rheum Dis. 2000 Jan;59(1):77-80 - PubMed
  15. Autoimmun Rev. 2008 Jun;7(6):440-4 - PubMed
  16. Neurology. 1994 Feb;44(2):223-6 - PubMed
  17. Ann N Y Acad Sci. 2007 Sep;1110:315-8 - PubMed
  18. Trends Pharmacol Sci. 2004 Jun;25(6):306-10 - PubMed
  19. Nat Clin Pract Neurol. 2007 Jan;3(1):36-44 - PubMed
  20. Clin Rev Allergy Immunol. 2005 Dec;29(3):327-32 - PubMed
  21. Angiology. 2002 Jan-Feb;53(1):113-7 - PubMed

Publication Types